Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir + nucleoside analogue
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy regimen consists of **tenofovir disoproxil fumarate (TDF)** administered alongside a **nucleoside analogue (NA)**, such as lamivudine, entecavir, telbivudine, or clevudine. It was specifically investigated by **Yonsei University** in the **SATIS (Switching from Adefovir To Tenofovir In patients with Suboptimal response)** trial. The regimen is designed for patients with chronic hepatitis B (CHB) who exhibit a suboptimal virological response to adefovir-based rescue therapy, often due to pre-existing nucleoside analogue resistance. Tenofovir is a potent nucleotide analogue that provides a high genetic barrier to resistance and effectively suppresses HBV DNA by inhibiting the viral polymerase. The combination strategy aims to achieve deeper viral suppression and increase the rates of HBeAg loss or seroconversion in treatment-experienced patients.
- Other names
- tenofovir disoproxil fumarate + nucleoside analogueNA + TDF combination therapy
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on tenofovir + nucleoside analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir + nucleoside analogue.